Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
2.965
-0.165 (-5.27%)
At close: Feb 21, 2025, 4:00 PM
2.970
+0.005 (0.17%)
After-hours: Feb 21, 2025, 5:28 PM EST
Prime Medicine Revenue
Prime Medicine had revenue of $209.00K in the quarter ending September 30, 2024. This brings the company's revenue in the last twelve months to $800.00K.
Revenue (ttm)
$800.00K
Revenue Growth
n/a
P/S Ratio
472.90
Revenue / Employee
$3,419
Employees
234
Market Cap
378.32M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | 5.21M | - | - |
Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
PRME News
- 23 days ago - Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm - PRNewsWire
- 3 months ago - Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies - Seeking Alpha
- 3 months ago - Wilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep Genomics - GlobeNewsWire
- 3 months ago - Prime Medicine to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress - GlobeNewsWire
- 4 months ago - Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings - GlobeNewsWire
- 5 months ago - Crude Oil Moves Higher; Prime Medicine Shares Spike Higher - Benzinga
- 5 months ago - Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline - Benzinga